Click for best price
Castration Resistant Prostate Cancer Treatment Market Size, Share 2022
Prostate cancer can be defined as it is a form of cancer that develops into male reproductive system. Most of the prostate cancer are slow growing and stable but sometimes it can spread from prostate (gland) to other part of body such as bone and lymph node. Initially prostate cancer does not pose any symptom but in severe cases it can cause pain during urination and can cause problem during sexual intercourse. Castration resistant prostate cancer is referred to as a prostate cancer that is spread to other parts of body and is resistant to medical or surgical treatment. Risk factor for castration resistant prostate cancer includes genetic predisposition, geriatric population, unhygienic diet, medication exposure and many sexual partners. Diagnosis for the detection of castration resistant prostate cancer includes prostate imaging, biopsy, tumor marker and staging test. Crucial factor about castration resistant prostate cancer is that it is resistant to medical and surgical treatment. However, other treatment options that are available in the market include hormone therapy, immune modulation, antiangiogenic treatment and bone targeted therapies.
This report contains market size and forecasts of Castration Resistant Prostate Cancer Treatment in Global, including the following market information:
Global Castration Resistant Prostate Cancer Treatment Market Revenue, 2017-2022, 2023-2028, ($ millions)
Global top five companies in 2021 (%)
The global Castration Resistant Prostate Cancer Treatment market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period.
The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.
Hormonal Therapy Segment to Reach $ Million by 2028, with a % CAGR in next six years.
The global key manufacturers of Castration Resistant Prostate Cancer Treatment include Active Biotech, Diagnocure, Glaxosmithkline, Northwest Biotherapeutics, Millennium Pharmaceuticals, Hologic, Spectrum Pharmaceuticals, Abbott Laboratories and Bayer Healthcare Pharmaceuticals. etc. In 2021, the global top five players have a share approximately % in terms of revenue.
We surveyed the Castration Resistant Prostate Cancer Treatment companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Castration Resistant Prostate Cancer Treatment Market, by Type, 2017-2022, 2023-2028 ($ millions)
Global Castration Resistant Prostate Cancer Treatment Market Segment Percentages, by Type, 2021 (%)
Hormonal Therapy
Adding An Anti-Androgen
Stopping An Anti-Androgen
Estrogens
Chemotherapy
Radiation Therapy
Others
Global Castration Resistant Prostate Cancer Treatment Market, by Application, 2017-2022, 2023-2028 ($ millions)
Global Castration Resistant Prostate Cancer Treatment Market Segment Percentages, by Application, 2021 (%)
Hospital
Ambulatory Surgical Centers
Global Castration Resistant Prostate Cancer Treatment Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions)
Global Castration Resistant Prostate Cancer Treatment Market Segment Percentages, By Region and Country, 2021 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Castration Resistant Prostate Cancer Treatment revenues in global market, 2017-2022 (estimated), ($ millions)
Key companies Castration Resistant Prostate Cancer Treatment revenues share in global market, 2021 (%)
Further, the report presents profiles of competitors in the market, key players include:
Active Biotech
Diagnocure
Glaxosmithkline
Northwest Biotherapeutics
Millennium Pharmaceuticals
Hologic
Spectrum Pharmaceuticals
Abbott Laboratories
Bayer Healthcare Pharmaceuticals
| Report Attributes |
Report Details |
| Report Title |
Castration Resistant Prostate Cancer Treatment Market - Global Outlook and Forecast 2022-2028 |
| Historical Year |
2018 to 2022 (Data from 2010 can be provided as per availability) |
| Base Year |
2021 |
| Forecast Year |
2029 |
| Number of Pages |
60 Pages |
| Customization Available |
Yes, the report can be customized as per your need. |
TABLE OF CONTENTS
1 Introduction to Research & Analysis Reports
1.1 Castration Resistant Prostate Cancer Treatment Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Castration Resistant Prostate Cancer Treatment Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global Castration Resistant Prostate Cancer Treatment Overall Market Size
2.1 Global Castration Resistant Prostate Cancer Treatment Market Size: 2021 VS 2028
2.2 Global Castration Resistant Prostate Cancer Treatment Market Size, Prospects & Forecasts: 2017-2028
2.3 Key Market Trends, Opportunity, Drivers and Restraints
2.3.1 Market Opportunities & Trends
2.3.2 Market Drivers
2.3.3 Market Restraints
3 Company Landscape
3.1 Top Castration Resistant Prostate Cancer Treatment Players in Global Market
3.2 Top Global Castration Resistant Prostate Cancer Treatment Companies Ranked by Revenue
3.3 Global Castration Resistant Prostate Cancer Treatment Revenue by Companies
3.4 Top 3 and Top 5 Castration Resistant Prostate Cancer Treatment Companies in Global Market, by Revenue in 2021
3.5 Global Companies Castration Resistant Prostate Cancer Treatment Product Type
3.6 Tier 1, Tier 2 and Tier 3 Castration Resistant Prostate Cancer Treatment Players in Global Market
3.6.1 List of Global Tier 1 Castration Resistant Prostate Cancer Treatment Companies
3.6.2 List of Global Tier 2 and Tier 3 Castration Resistant Prostate Cancer Treatment Companies
4 Market Sights by Product
4.1 Overview
4.1.1 by Type - Global Castration Resistant Prostate Cancer Treatment Market Size Markets, 2021 & 2028
4.1.2 Hormonal Therapy
4.1.3 Adding An Anti-Androgen
4.1.4 Stopping An Anti-Androgen
4.1.5 Estrogens
4.1.6 Chemotherapy
4.1.7 Radiation Therapy
4.1.8 Others
4.2 By Type - Global Castration Resistant Prostate Cancer Treatment Revenue & Forecasts
4.2.1 By Type - Global Castration Resistant Prostate Cancer Treatment Revenue, 2017-2022
4.2.2 By Type - Global Castration Resistant Prostate Cancer Treatment Revenue, 2023-2028
4.2.3 By Type - Global Castration Resistant Prostate Cancer Treatment Revenue Market Share, 2017-2028
5 Sights by Application
5.1 Overview
5.1.1 By Application - Global Castration Resistant Prostate Cancer Treatment Market Size, 2021 & 2028
5.1.2 Hospital
5.1.3 Ambulatory Surgical Centers
5.2 By Application - Global Castration Resistant Prostate Cancer Treatment Revenue & Forecasts
5.2.1 By Application - Global Castration Resistant Prostate Cancer Treatment Revenue, 2017-2022
5.2.2 By Application - Global Castration Resistant Prostate Cancer Treatment Revenue, 2023-2028
5.2.3 By Application - Global Castration Resistant Prostate Cancer Treatment Revenue Market Share, 2017-2028
6 Sights by Region
6.1 By Region - Global Castration Resistant Prostate Cancer Treatment Market Size, 2021 & 2028
6.2 By Region - Global Castration Resistant Prostate Cancer Treatment Revenue & Forecasts
6.2.1 By Region - Global Castration Resistant Prostate Cancer Treatment Revenue, 2017-2022
6.2.2 By Region - Global Castration Resistant Prostate Cancer Treatment Revenue, 2023-2028
6.2.3 By Region - Global Castration Resistant Prostate Cancer Treatment Revenue Market Share, 2017-2028
6.3 North America
6.3.1 By Country - North America Castration Resistant Prostate Cancer Treatment Revenue, 2017-2028
6.3.2 US Castration Resistant Prostate Cancer Treatment Market Size, 2017-2028
6.3.3 Canada Castration Resistant Prostate Cancer Treatment Market Size, 2017-2028
6.3.4 Mexico Castration Resistant Prostate Cancer Treatment Market Size, 2017-2028
6.4 Europe
6.4.1 By Country - Europe Castration Resistant Prostate Cancer Treatment Revenue, 2017-2028
6.4.2 Germany Castration Resistant Prostate Cancer Treatment Market Size, 2017-2028
6.4.3 France Castration Resistant Prostate Cancer Treatment Market Size, 2017-2028
6.4.4 U.K. Castration Resistant Prostate Cancer Treatment Market Size, 2017-2028
6.4.5 Italy Castration Resistant Prostate Cancer Treatment Market Size, 2017-2028
6.4.6 Russia Castration Resistant Prostate Cancer Treatment Market Size, 2017-2028
6.4.7 Nordic Countries Castration Resistant Prostate Cancer Treatment Market Size, 2017-2028
6.4.8 Benelux Castration Resistant Prostate Cancer Treatment Market Size, 2017-2028
6.5 Asia
6.5.1 By Region - Asia Castration Resistant Prostate Cancer Treatment Revenue, 2017-2028
6.5.2 China Castration Resistant Prostate Cancer Treatment Market Size, 2017-2028
6.5.3 Japan Castration Resistant Prostate Cancer Treatment Market Size, 2017-2028
6.5.4 South Korea Castration Resistant Prostate Cancer Treatment Market Size, 2017-2028
6.5.5 Southeast Asia Castration Resistant Prostate Cancer Treatment Market Size, 2017-2028
6.5.6 India Castration Resistant Prostate Cancer Treatment Market Size, 2017-2028
6.6 South America
6.6.1 By Country - South America Castration Resistant Prostate Cancer Treatment Revenue, 2017-2028
6.6.2 Brazil Castration Resistant Prostate Cancer Treatment Market Size, 2017-2028
6.6.3 Argentina Castration Resistant Prostate Cancer Treatment Market Size, 2017-2028
6.7 Middle East & Africa
6.7.1 By Country - Middle East & Africa Castration Resistant Prostate Cancer Treatment Revenue, 2017-2028
6.7.2 Turkey Castration Resistant Prostate Cancer Treatment Market Size, 2017-2028
6.7.3 Israel Castration Resistant Prostate Cancer Treatment Market Size, 2017-2028
6.7.4 Saudi Arabia Castration Resistant Prostate Cancer Treatment Market Size, 2017-2028
6.7.5 UAE Castration Resistant Prostate Cancer Treatment Market Size, 2017-2028
7 Players Profiles
7.1 Active Biotech
7.1.1 Active Biotech Corporate Summary
7.1.2 Active Biotech Business Overview
7.1.3 Active Biotech Castration Resistant Prostate Cancer Treatment Major Product Offerings
7.1.4 Active Biotech Castration Resistant Prostate Cancer Treatment Revenue in Global Market (2017-2022)
7.1.5 Active Biotech Key News
7.2 Diagnocure
7.2.1 Diagnocure Corporate Summary
7.2.2 Diagnocure Business Overview
7.2.3 Diagnocure Castration Resistant Prostate Cancer Treatment Major Product Offerings
7.2.4 Diagnocure Castration Resistant Prostate Cancer Treatment Revenue in Global Market (2017-2022)
7.2.5 Diagnocure Key News
7.3 Glaxosmithkline
7.3.1 Glaxosmithkline Corporate Summary
7.3.2 Glaxosmithkline Business Overview
7.3.3 Glaxosmithkline Castration Resistant Prostate Cancer Treatment Major Product Offerings
7.3.4 Glaxosmithkline Castration Resistant Prostate Cancer Treatment Revenue in Global Market (2017-2022)
7.3.5 Glaxosmithkline Key News
7.4 Northwest Biotherapeutics
7.4.1 Northwest Biotherapeutics Corporate Summary
7.4.2 Northwest Biotherapeutics Business Overview
7.4.3 Northwest Biotherapeutics Castration Resistant Prostate Cancer Treatment Major Product Offerings
7.4.4 Northwest Biotherapeutics Castration Resistant Prostate Cancer Treatment Revenue in Global Market (2017-2022)
7.4.5 Northwest Biotherapeutics Key News
7.5 Millennium Pharmaceuticals
7.5.1 Millennium Pharmaceuticals Corporate Summary
7.5.2 Millennium Pharmaceuticals Business Overview
7.5.3 Millennium Pharmaceuticals Castration Resistant Prostate Cancer Treatment Major Product Offerings
7.5.4 Millennium Pharmaceuticals Castration Resistant Prostate Cancer Treatment Revenue in Global Market (2017-2022)
7.5.5 Millennium Pharmaceuticals Key News
7.6 Hologic
7.6.1 Hologic Corporate Summary
7.6.2 Hologic Business Overview
7.6.3 Hologic Castration Resistant Prostate Cancer Treatment Major Product Offerings
7.6.4 Hologic Castration Resistant Prostate Cancer Treatment Revenue in Global Market (2017-2022)
7.6.5 Hologic Key News
7.7 Spectrum Pharmaceuticals
7.7.1 Spectrum Pharmaceuticals Corporate Summary
7.7.2 Spectrum Pharmaceuticals Business Overview
7.7.3 Spectrum Pharmaceuticals Castration Resistant Prostate Cancer Treatment Major Product Offerings
7.7.4 Spectrum Pharmaceuticals Castration Resistant Prostate Cancer Treatment Revenue in Global Market (2017-2022)
7.7.5 Spectrum Pharmaceuticals Key News
7.8 Abbott Laboratories
7.8.1 Abbott Laboratories Corporate Summary
7.8.2 Abbott Laboratories Business Overview
7.8.3 Abbott Laboratories Castration Resistant Prostate Cancer Treatment Major Product Offerings
7.8.4 Abbott Laboratories Castration Resistant Prostate Cancer Treatment Revenue in Global Market (2017-2022)
7.8.5 Abbott Laboratories Key News
7.9 Bayer Healthcare Pharmaceuticals
7.9.1 Bayer Healthcare Pharmaceuticals Corporate Summary
7.9.2 Bayer Healthcare Pharmaceuticals Business Overview
7.9.3 Bayer Healthcare Pharmaceuticals Castration Resistant Prostate Cancer Treatment Major Product Offerings
7.9.4 Bayer Healthcare Pharmaceuticals Castration Resistant Prostate Cancer Treatment Revenue in Global Market (2017-2022)
7.9.5 Bayer Healthcare Pharmaceuticals Key News
8 Conclusion
9 Appendix
9.1 Note
9.2 Examples of Clients
9.3 Disclaimer
LIST OF TABLES & FIGURES
List of Tables
Table 1. Castration Resistant Prostate Cancer Treatment Market Opportunities & Trends in Global Market
Table 2. Castration Resistant Prostate Cancer Treatment Market Drivers in Global Market
Table 3. Castration Resistant Prostate Cancer Treatment Market Restraints in Global Market
Table 4. Key Players of Castration Resistant Prostate Cancer Treatment in Global Market
Table 5. Top Castration Resistant Prostate Cancer Treatment Players in Global Market, Ranking by Revenue (2021)
Table 6. Global Castration Resistant Prostate Cancer Treatment Revenue by Companies, (US$, Mn), 2017-2022
Table 7. Global Castration Resistant Prostate Cancer Treatment Revenue Share by Companies, 2017-2022
Table 8. Global Companies Castration Resistant Prostate Cancer Treatment Product Type
Table 9. List of Global Tier 1 Castration Resistant Prostate Cancer Treatment Companies, Revenue (US$, Mn) in 2021 and Market Share
Table 10. List of Global Tier 2 and Tier 3 Castration Resistant Prostate Cancer Treatment Companies, Revenue (US$, Mn) in 2021 and Market Share
Table 11. By Type ? Global Castration Resistant Prostate Cancer Treatment Revenue, (US$, Mn), 2021 & 2028
Table 12. By Type - Castration Resistant Prostate Cancer Treatment Revenue in Global (US$, Mn), 2017-2022
Table 13. By Type - Castration Resistant Prostate Cancer Treatment Revenue in Global (US$, Mn), 2023-2028
Table 14. By Application ? Global Castration Resistant Prostate Cancer Treatment Revenue, (US$, Mn), 2021 & 2028
Table 15. By Application - Castration Resistant Prostate Cancer Treatment Revenue in Global (US$, Mn), 2017-2022
Table 16. By Application - Castration Resistant Prostate Cancer Treatment Revenue in Global (US$, Mn), 2023-2028
Table 17. By Region ? Global Castration Resistant Prostate Cancer Treatment Revenue, (US$, Mn), 2021 & 2028
Table 18. By Region - Global Castration Resistant Prostate Cancer Treatment Revenue (US$, Mn), 2017-2022
Table 19. By Region - Global Castration Resistant Prostate Cancer Treatment Revenue (US$, Mn), 2023-2028
Table 20. By Country - North America Castration Resistant Prostate Cancer Treatment Revenue, (US$, Mn), 2017-2022
Table 21. By Country - North America Castration Resistant Prostate Cancer Treatment Revenue, (US$, Mn), 2023-2028
Table 22. By Country - Europe Castration Resistant Prostate Cancer Treatment Revenue, (US$, Mn), 2017-2022
Table 23. By Country - Europe Castration Resistant Prostate Cancer Treatment Revenue, (US$, Mn), 2023-2028
Table 24. By Region - Asia Castration Resistant Prostate Cancer Treatment Revenue, (US$, Mn), 2017-2022
Table 25. By Region - Asia Castration Resistant Prostate Cancer Treatment Revenue, (US$, Mn), 2023-2028
Table 26. By Country - South America Castration Resistant Prostate Cancer Treatment Revenue, (US$, Mn), 2017-2022
Table 27. By Country - South America Castration Resistant Prostate Cancer Treatment Revenue, (US$, Mn), 2023-2028
Table 28. By Country - Middle East & Africa Castration Resistant Prostate Cancer Treatment Revenue, (US$, Mn), 2017-2022
Table 29. By Country - Middle East & Africa Castration Resistant Prostate Cancer Treatment Revenue, (US$, Mn), 2023-2028
Table 30. Active Biotech Corporate Summary
Table 31. Active Biotech Castration Resistant Prostate Cancer Treatment Product Offerings
Table 32. Active Biotech Castration Resistant Prostate Cancer Treatment Revenue (US$, Mn), (2017-2022)
Table 33. Diagnocure Corporate Summary
Table 34. Diagnocure Castration Resistant Prostate Cancer Treatment Product Offerings
Table 35. Diagnocure Castration Resistant Prostate Cancer Treatment Revenue (US$, Mn), (2017-2022)
Table 36. Glaxosmithkline Corporate Summary
Table 37. Glaxosmithkline Castration Resistant Prostate Cancer Treatment Product Offerings
Table 38. Glaxosmithkline Castration Resistant Prostate Cancer Treatment Revenue (US$, Mn), (2017-2022)
Table 39. Northwest Biotherapeutics Corporate Summary
Table 40. Northwest Biotherapeutics Castration Resistant Prostate Cancer Treatment Product Offerings
Table 41. Northwest Biotherapeutics Castration Resistant Prostate Cancer Treatment Revenue (US$, Mn), (2017-2022)
Table 42. Millennium Pharmaceuticals Corporate Summary
Table 43. Millennium Pharmaceuticals Castration Resistant Prostate Cancer Treatment Product Offerings
Table 44. Millennium Pharmaceuticals Castration Resistant Prostate Cancer Treatment Revenue (US$, Mn), (2017-2022)
Table 45. Hologic Corporate Summary
Table 46. Hologic Castration Resistant Prostate Cancer Treatment Product Offerings
Table 47. Hologic Castration Resistant Prostate Cancer Treatment Revenue (US$, Mn), (2017-2022)
Table 48. Spectrum Pharmaceuticals Corporate Summary
Table 49. Spectrum Pharmaceuticals Castration Resistant Prostate Cancer Treatment Product Offerings
Table 50. Spectrum Pharmaceuticals Castration Resistant Prostate Cancer Treatment Revenue (US$, Mn), (2017-2022)
Table 51. Abbott Laboratories Corporate Summary
Table 52. Abbott Laboratories Castration Resistant Prostate Cancer Treatment Product Offerings
Table 53. Abbott Laboratories Castration Resistant Prostate Cancer Treatment Revenue (US$, Mn), (2017-2022)
Table 54. Bayer Healthcare Pharmaceuticals Corporate Summary
Table 55. Bayer Healthcare Pharmaceuticals Castration Resistant Prostate Cancer Treatment Product Offerings
Table 56. Bayer Healthcare Pharmaceuticals Castration Resistant Prostate Cancer Treatment Revenue (US$, Mn), (2017-2022)
List of Figures
Figure 1. Castration Resistant Prostate Cancer Treatment Segment by Type in 2021
Figure 2. Castration Resistant Prostate Cancer Treatment Segment by Application in 2021
Figure 3. Global Castration Resistant Prostate Cancer Treatment Market Overview: 2021
Figure 4. Key Caveats
Figure 5. Global Castration Resistant Prostate Cancer Treatment Market Size: 2021 VS 2028 (US$, Mn)
Figure 6. Global Castration Resistant Prostate Cancer Treatment Revenue, 2017-2028 (US$, Mn)
Figure 7. The Top 3 and 5 Players Market Share by Castration Resistant Prostate Cancer Treatment Revenue in 2021
Figure 8. By Type - Global Castration Resistant Prostate Cancer Treatment Revenue Market Share, 2017-2028
Figure 9. By Application - Global Castration Resistant Prostate Cancer Treatment Revenue Market Share, 2017-2028
Figure 10. By Region - Global Castration Resistant Prostate Cancer Treatment Revenue Market Share, 2017-2028
Figure 11. By Country - North America Castration Resistant Prostate Cancer Treatment Revenue Market Share, 2017-2028
Figure 12. US Castration Resistant Prostate Cancer Treatment Revenue, (US$, Mn), 2017-2028
Figure 13. Canada Castration Resistant Prostate Cancer Treatment Revenue, (US$, Mn), 2017-2028
Figure 14. Mexico Castration Resistant Prostate Cancer Treatment Revenue, (US$, Mn), 2017-2028
Figure 15. By Country - Europe Castration Resistant Prostate Cancer Treatment Revenue Market Share, 2017-2028
Figure 16. Germany Castration Resistant Prostate Cancer Treatment Revenue, (US$, Mn), 2017-2028
Figure 17. France Castration Resistant Prostate Cancer Treatment Revenue, (US$, Mn), 2017-2028
Figure 18. U.K. Castration Resistant Prostate Cancer Treatment Revenue, (US$, Mn), 2017-2028
Figure 19. Italy Castration Resistant Prostate Cancer Treatment Revenue, (US$, Mn), 2017-2028
Figure 20. Russia Castration Resistant Prostate Cancer Treatment Revenue, (US$, Mn), 2017-2028
Figure 21. Nordic Countries Castration Resistant Prostate Cancer Treatment Revenue, (US$, Mn), 2017-2028
Figure 22. Benelux Castration Resistant Prostate Cancer Treatment Revenue, (US$, Mn), 2017-2028
Figure 23. By Region - Asia Castration Resistant Prostate Cancer Treatment Revenue Market Share, 2017-2028
Figure 24. China Castration Resistant Prostate Cancer Treatment Revenue, (US$, Mn), 2017-2028
Figure 25. Japan Castration Resistant Prostate Cancer Treatment Revenue, (US$, Mn), 2017-2028
Figure 26. South Korea Castration Resistant Prostate Cancer Treatment Revenue, (US$, Mn), 2017-2028
Figure 27. Southeast Asia Castration Resistant Prostate Cancer Treatment Revenue, (US$, Mn), 2017-2028
Figure 28. India Castration Resistant Prostate Cancer Treatment Revenue, (US$, Mn), 2017-2028
Figure 29. By Country - South America Castration Resistant Prostate Cancer Treatment Revenue Market Share, 2017-2028
Figure 30. Brazil Castration Resistant Prostate Cancer Treatment Revenue, (US$, Mn), 2017-2028
Figure 31. Argentina Castration Resistant Prostate Cancer Treatment Revenue, (US$, Mn), 2017-2028
Figure 32. By Country - Middle East & Africa Castration Resistant Prostate Cancer Treatment Revenue Market Share, 2017-2028
Figure 33. Turkey Castration Resistant Prostate Cancer Treatment Revenue, (US$, Mn), 2017-2028
Figure 34. Israel Castration Resistant Prostate Cancer Treatment Revenue, (US$, Mn), 2017-2028
Figure 35. Saudi Arabia Castration Resistant Prostate Cancer Treatment Revenue, (US$, Mn), 2017-2028
Figure 36. UAE Castration Resistant Prostate Cancer Treatment Revenue, (US$, Mn), 2017-2028
Figure 37. Active Biotech Castration Resistant Prostate Cancer Treatment Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 38. Diagnocure Castration Resistant Prostate Cancer Treatment Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 39. Glaxosmithkline Castration Resistant Prostate Cancer Treatment Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 40. Northwest Biotherapeutics Castration Resistant Prostate Cancer Treatment Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 41. Millennium Pharmaceuticals Castration Resistant Prostate Cancer Treatment Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 42. Hologic Castration Resistant Prostate Cancer Treatment Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 43. Spectrum Pharmaceuticals Castration Resistant Prostate Cancer Treatment Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 44. Abbott Laboratories Castration Resistant Prostate Cancer Treatment Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 45. Bayer Healthcare Pharmaceuticals Castration Resistant Prostate Cancer Treatment Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
